NGM Biopharmaceuticals Inc (OQ:NGM)

Business Focus: Bio Therapeutic Drugs

Jun 10, 2019 03:00 am ET
NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Aetna Wun Trombley,...
Jun 05, 2019 03:00 am ET
NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that it will present new data from a Phase 1b study of NGM313 at the 79th Scientific...
May 16, 2019 12:05 pm ET
NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today provided a business update and reported first quarter 2019 financial results for the period...
Apr 08, 2019 12:30 pm ET
NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative therapeutics for patients, today announced multiple presentations at European Association for the...
Apr 03, 2019 04:58 pm ET
NGM Bio Announces Pricing of Initial Public Offering
NGM Biopharmaceuticals, Inc. (“NGM”) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a price to the public of $16.00 per share. In addition, NGM has granted the underwriters a 30-day option to...